System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 18 citations

PubMed: 33572642 DOI: 10.3390/cancers13030539

Systematic Review and Metanalysis of Oncomarkers in IPF Patients and Serial Changes of Oncomarkers in a Prospective Italian Real-Life Case Series.

Cancers (Basel) 13(3)

Authors: Miriana d'Alessandro, Laura Bergantini, Elena Torricelli, Paolo Cameli, Federico Lavorini, Maria Pieroni, Rosa Metella Refini, Piersante Sestini, Elena Bargagli

Affiliations

  • Respiratory Diseases and Lung Transplantation, Department of Medical and Surgical Sciences & Neurosciences, Siena University Hospital, 53100 Siena, Italy.
  • Section of Respiratory Medicine, Department of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy.

Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is a severe progressive interstitial lung disease. At 5-year follow-up, 15% of IPF patients develop lung cancer, which significantly reduces the survival rate. Here we review the literature on the clinical role of oncomarkers in IPF progression, and describe the trend of routine oncomarkers in IPF patients over the longest follow-up yet reported.

MATERIALS AND METHODS

A systematic search of the literature in PubMed was performed to find relevant studies published up to 24 September 2020. The most common oncomarkers were chosen to select papers related to pulmonary fibrosis. Then, 24 IPF patients and 25 non-IPF patients, followed at Careggi ILD Referral Centre and Siena Regional Referral Centre for ILD, were enrolled consecutively.

RESULTS

A few studies reported an association between serum oncomarkers and severity of IPF. NSE, CEA, Ca19.9, and Ca125 were higher in the IPF, than in the non-IPF, group at every follow-up ( < 0.05). Ca15.3 concentrations were higher in the IPF, than the non-IPF, group at t3 ( = 0.0080) and t4 ( = 0.0168). To improve the specificity and sensitivity of Ca15.3, a panel of biomarkers was analyzed, with the IPF group as dependent variable, and chitotriosidase, Cyfra 21.1, Ca15.3, Ca125, and Ca19.9 as independent variables.

CONCLUSIONS

This study focused on the discovery of multiple biomarker signatures, such as combinations of oncomarkers, that are widely and routinely available in biochemistry laboratories. The combination of clinical parameters and biological markers could help achieve more accurate results regarding prognosis and response to treatment in IPF. Our results could pave the way for a more "personalized" medical approach to patients affected by IPF.

MeSH

Biomarkers, Lung Neoplasms, Idiopathic Pulmonary Fibrosis

Cited by